Target Group Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Target Group has been growing earnings at an average annual rate of 31.4%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 95.8% per year.
Belangrijke informatie
31.4%
Groei van de winst
44.7%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 6.0% |
| Inkomstengroei | 95.8% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | -1.0% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
Geen updates
Opbrengsten en kosten
Hoe Target Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 7 | 0 | 2 | 0 |
| 31 Mar 24 | 6 | 0 | 2 | 0 |
| 31 Dec 23 | 4 | 0 | 1 | 0 |
| 30 Sep 23 | 2 | -4 | 1 | 0 |
| 30 Jun 23 | 1 | -4 | 1 | 0 |
| 31 Mar 23 | 0 | -5 | 0 | 0 |
| 31 Dec 22 | 0 | -5 | 0 | 0 |
| 30 Sep 22 | 0 | -1 | 0 | 0 |
| 30 Jun 22 | 0 | 2 | 0 | 0 |
| 31 Mar 22 | 0 | 2 | 0 | 0 |
| 31 Dec 21 | 0 | 0 | 0 | 0 |
| 30 Sep 21 | 0 | -5 | 1 | 0 |
| 30 Jun 21 | 0 | -11 | 1 | 0 |
| 31 Mar 21 | 0 | -13 | 1 | 0 |
| 31 Dec 20 | 0 | -7 | 1 | 0 |
| 30 Sep 20 | 0 | -8 | 2 | 0 |
| 30 Jun 20 | 0 | -5 | 3 | 0 |
| 31 Mar 20 | 0 | -6 | 4 | 0 |
| 31 Dec 19 | 0 | -10 | 5 | 0 |
| 30 Sep 19 | 0 | -4 | 4 | 0 |
| 30 Jun 19 | 0 | -5 | 4 | 0 |
| 31 Mar 19 | 0 | -3 | 2 | 0 |
| 31 Dec 18 | 0 | -2 | 1 | 0 |
| 30 Sep 18 | 0 | -3 | 1 | 0 |
| 30 Jun 18 | 0 | -2 | 1 | 0 |
| 31 Mar 18 | 0 | -1 | 1 | 0 |
| 31 Dec 17 | 0 | -2 | 1 | 0 |
| 30 Sep 17 | 0 | -1 | 1 | 0 |
| 30 Jun 17 | 0 | -2 | 1 | 0 |
| 31 Mar 17 | 0 | -2 | 1 | 0 |
| 31 Dec 16 | 0 | -2 | 2 | 0 |
| 30 Sep 16 | 0 | -5 | 4 | 0 |
| 30 Jun 16 | 0 | -3 | 3 | 0 |
| 31 Mar 16 | 0 | -3 | 3 | 0 |
| 31 Dec 15 | 0 | -3 | 2 | 0 |
| 30 Sep 15 | 0 | -1 | 1 | 0 |
| 30 Jun 15 | 0 | -1 | 0 | 0 |
| 31 Mar 15 | 0 | 0 | 0 | 0 |
| 31 Dec 14 | 0 | 0 | 0 | 0 |
Kwaliteitswinsten: CBDY is currently unprofitable.
Groeiende winstmarge: CBDY is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: CBDY is unprofitable, but has reduced losses over the past 5 years at a rate of 31.4% per year.
Versnelling van de groei: Unable to compare CBDY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: CBDY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Rendement op eigen vermogen
Hoge ROE: CBDY's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.